Overview

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III trial.
Phase:
Phase 2
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
Treatments:
Denileukin diftitox
Etanercept
Interleukin-2
Mycophenolate mofetil
Mycophenolic Acid
Pentostatin